The 'Dr. Google' Dilemma: Why Pet Owners Bypass Vets for Supplements

SALEM, Ore. – September 29, 2026 — Trust is the ultimate currency in healthcare, and for veterinarians, that currency is trading at an all-time high. A recent survey reveals that 72% of pet owners explicitly trust their animal's doctor, a stark contrast to the 58% who say the same about their own human physicians. Yet, when it comes to the booming pet supplement market, this professional reverence is failing to translate into consumer behavior.

According to the newly released Pet Wellness Consumer Trends Report 2026 from Oregon-based wellness brand Lillie&Lee, a behavioral divide is reshaping the multi-billion-dollar companion animal market. When selecting a new supplement, only 35.3% of pet parents rely on their veterinarian's recommendation. Meanwhile, a nearly equal cohort—29.2%—bypasses clinical guidance entirely, opting to research and purchase products on their own.

This disconnect highlights a growing challenge in veterinary medicine: the rise of the empowered, yet isolated, consumer. As the "humanization" of pets accelerates, owners are applying their own preventative health mindsets to their animals, often outpacing the veterinary industry's ability to provide standardized guidance on functional supplements and alternative therapies.

The Trust Disconnect in Pet Wellness

The findings from Lillie&Lee, an enterprise founded by internationally recognized animal-rescue advocate Lee Asher, underscore a critical gap in the market. The company, which evolved from Asher House Wellness and was named for Asher's first rescue St. Bernard, surveyed a highly engaged demographic to understand the friction points in pet care purchasing.

"Pet parents trust their vet more than almost anyone but a lot of them are still making supplement decisions solo, without the information they'd need to bring their vet into that conversation," said Lee Asher, founder of Lillie&Lee. "That's the gap we exist to close."

The survey's demographic—predominantly female, with an average age of 63 and highly invested in daily pet care routines—represents the core engine of the modern pet wellness economy. These are consumers who view proactive health not as an adjacency to pet care, but as its central pillar. However, their willingness to self-prescribe points to a systemic bottleneck in how nutritional and functional information is disseminated in the exam room.

Navigating the $1.7 Billion CBD Boom

The stakes of this communication breakdown are massive. The global pet supplement market is projected to expand from roughly $2.43 billion in 2025 to $2.62 billion this year, and is on track to reach $3.57 billion by 2030. But it is the hemp-derived sector that is truly testing the boundaries of veterinary medicine.

Pet CBD is projected to expand at an average annual compound growth rate of nearly 32% through 2030, reaching an estimated $1.7 billion market size. This hyper-growth is driven by consumers moving past historical stigmas and seeking alternative treatments for canine anxiety, joint pain, and age-related ailments.

"Every number in this report points to the same opportunity," said D.J. Gugenheim, partner and president of Lillie&Lee. "Pet parents want their vet's input, the market is growing whether or not vets are part of that conversation, and our job is to make sure they have something worth weighing in on."

Yet, veterinarians are often notably absent from these conversations, constrained by a complex web of regulatory and liability hurdles. The American Veterinary Medical Association (AVMA) and state licensing boards generally advise caution, noting the lack of FDA approval and robust clinical trials for most animal CBD products. Because these products lack "Generally Recognized as Safe" (GRAS) status from the FDA's Center for Veterinary Medicine, practitioners face potential legal exposure if they formally prescribe or initiate recommendations for unapproved treatments.

"We are operating in a regulatory blind spot," noted one practicing small-animal veterinarian familiar with state licensing pressures. "Clients want to know if a hemp product will help their aging retriever's joints, but without FDA approval or standardized clinical trials, recommending a specific brand puts our licenses at risk. It forces the client to go to 'Dr. Google' instead."

Radical Transparency as a Market Differentiator

With the FDA largely refraining from pre-market approval for pet supplements—leaving the onus on manufacturers to ensure safety—the industry has become a fragmented landscape of varying quality. Organizations like the National Animal Supplement Council (NASC) have attempted to instill quality control standards, but the burden of proof ultimately falls on individual brands to win over skeptical clinicians.

To bridge this divide, progressive companies are leveraging radical transparency as a core business strategy. Lillie&Lee's approach centers on arming both the consumer and the clinician with identical data simultaneously. Every product in their American-made, hemp-derived line is backed by a published, third-party Certificate of Analysis (COA).

A comprehensive COA verifies the product's active ingredients, confirms potency, and screens for contaminants such as heavy metals, pesticides, and microbial impurities. By making these batch-specific documents publicly available, the brand allows owners to verify purity before a supplement ever reaches the veterinary exam room.

"Pre-market approval doesn't exist here like it does for pharmaceuticals," an industry regulatory analyst explained. "The onus is entirely on the manufacturer to prove their product isn't just snake oil. When a brand provides a comprehensive, third-party COA, they are effectively doing the heavy lifting for the veterinarian, mitigating the professional risk of giving a product the green light."

The strategy appears to be working. According to internal reports, a growing number of customers are utilizing these public COAs to initiate conversations with their veterinarians, successfully securing professional approval before finalizing their purchases.

The Future of the Veterinary Conversation

As the pet care industry continues its shift toward "shared wellness"—where owners apply their personal longevity and health routines to their animal companions—the demand for functional supplements will only intensify. The behavioral divide identified in the 2026 trends report serves as a warning sign for the industry: consumer demand is moving faster than traditional clinical consensus.

For veterinarians, the challenge lies in finding safe, legally compliant ways to guide clients through an unregulated market. For manufacturers, the mandate is clear. In a landscape where product availability is ubiquitous, clinical-grade transparency is the new barrier to entry. Brands that fail to provide verifiable data will find themselves relegated to the risky margins of online self-research, while those that prioritize rigorous third-party testing will successfully close the gap between consumer enthusiasm and professional trust.